Fortress Biotech (FBIO)
Fortress Biotech on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.5M
Short interest
settlement 2026-10-15
16.1
Days to cover
-2.3 days vs prior
53.5%
Short share of volume
2026-11-02
985
Fails to deliver
settlement 2026-10-14
Fri 13 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in FBIO is 4,522,696 shares, down 584,898 shares over the last month. Over the last 48 readings it ranged from 2,622,535 shares (31 October 2024) to 5,784,483 shares (31 July 2026). At the reported average volume of 281K shares a day that is 16.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/fbio" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,522,696 | -7.7% | 281,033 | 16.09 |
| 2026-09-30 | 4,898,052 | -4.1% | 266,430 | 18.38 |
| 2026-09-15 | 5,107,594 | -6.2% | 269,219 | 18.97 |
| 2026-08-31 | 5,443,900 | -2.4% | 454,930 | 11.97 |
| 2026-08-14 | 5,575,779 | -3.6% | 973,819 | 5.73 |
| 2026-07-31 | 5,784,483 | +7.5% | 481,097 | 12.02 |
| 2026-07-15 | 5,380,621 | +1.4% | 647,819 | 8.31 |
| 2026-06-30 | 5,305,659 | +3.2% | 627,060 | 8.46 |
| 2026-06-15 | 5,143,035 | +1.0% | 466,730 | 11.02 |
| 2026-05-29 | 5,090,428 | +4.3% | 450,027 | 11.31 |
| 2026-05-15 | 4,882,556 | +5.0% | 336,274 | 14.52 |
| 2026-04-30 | 4,649,541 | +2.3% | 261,438 | 17.78 |
| 2026-04-15 | 4,546,587 | +4.2% | 540,469 | 8.41 |
| 2026-03-31 | 4,361,750 | +2.0% | 476,794 | 9.15 |
| 2026-03-13 | 4,277,281 | -4.6% | 445,398 | 9.60 |
| 2026-02-27 | 4,484,322 | +4.0% | 1,325,556 | 3.38 |
| 2026-02-13 | 4,310,143 | -6.0% | 559,045 | 7.71 |
| 2026-01-30 | 4,583,530 | +2.0% | 565,839 | 8.10 |
| 2026-01-15 | 4,491,241 | +11.0% | 1,883,147 | 2.38 |
| 2025-12-31 | 4,045,115 | +11.6% | 568,048 | 7.12 |
| 2025-12-15 | 3,624,744 | -2.2% | 496,130 | 7.31 |
| 2025-11-28 | 3,706,394 | -6.8% | 302,267 | 12.26 |
| 2025-11-14 | 3,976,655 | +13.4% | 360,458 | 11.03 |
| 2025-10-31 | 3,505,973 | +3.8% | 436,565 | 8.03 |
| 2025-10-15 | 3,378,367 | -9.9% | 1,518,408 | 2.22 |
| 2025-09-30 | 3,750,911 | -1.1% | 1,301,775 | 2.88 |
| 2025-09-15 | 3,790,877 | +25.2% | 1,913,958 | 1.98 |
| 2025-08-29 | 3,027,305 | +8.5% | 628,653 | 4.82 |
| 2025-08-15 | 2,791,229 | -6.5% | 235,107 | 11.87 |
| 2025-07-31 | 2,983,698 | -4.6% | 180,496 | 16.53 |
| 2025-07-15 | 3,128,751 | -2.1% | 243,085 | 12.87 |
| 2025-06-30 | 3,196,641 | -3.0% | 192,999 | 16.56 |
| 2025-06-13 | 3,294,028 | -2.0% | 266,937 | 12.34 |
| 2025-05-30 | 3,362,646 | -4.2% | 210,623 | 15.97 |
| 2025-05-15 | 3,509,189 | -4.8% | 139,049 | 25.24 |
| 2025-04-30 | 3,687,086 | +1.5% | 154,540 | 23.86 |
| 2025-04-15 | 3,632,746 | -0.0% | 205,758 | 17.66 |
| 2025-03-31 | 3,633,082 | -3.7% | 296,759 | 12.24 |
| 2025-03-14 | 3,773,541 | +2.6% | 457,486 | 8.25 |
| 2025-02-28 | 3,677,307 | -0.5% | 265,640 | 13.84 |
| 2025-02-14 | 3,694,505 | +3.2% | 305,355 | 12.10 |
| 2025-01-31 | 3,580,429 | +3.0% | 270,168 | 13.25 |
| 2025-01-15 | 3,476,154 | +2.1% | 619,947 | 5.61 |
| 2024-12-31 | 3,402,998 | +9.5% | 745,606 | 4.56 |
| 2024-12-13 | 3,106,786 | +10.3% | 825,694 | 3.76 |
| 2024-11-29 | 2,816,322 | -3.4% | 514,227 | 5.48 |
| 2024-11-15 | 2,915,257 | +11.2% | 617,322 | 4.72 |
| 2024-10-31 | 2,622,535 | +1.9% | 576,160 | 4.55 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of FBIO volume is 53.5%, up 5.1 points over the last five sessions. Over the last 30 readings it ranged from 22.1% (9 October 2026) to 73.6% (19 October 2026). The latest reading is 15.3 points above the 30-session average of 38.2%, on 91K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 49K | 91K | 53.5% | 0 |
| 2026-10-30 | 61K | 114K | 52.9% | 600 |
| 2026-10-29 | 84K | 137K | 61.4% | 98 |
| 2026-10-28 | 24K | 81K | 30.0% | 0 |
| 2026-10-27 | 31K | 84K | 36.9% | 0 |
| 2026-10-26 | 26K | 54K | 48.4% | 0 |
| 2026-10-23 | 48K | 119K | 40.6% | 145 |
| 2026-10-22 | 31K | 112K | 27.3% | 0 |
| 2026-10-21 | 36K | 98K | 36.5% | 1,300 |
| 2026-10-20 | 37K | 145K | 25.6% | 667 |
| 2026-10-19 | 114K | 155K | 73.6% | 0 |
| 2026-10-16 | 49K | 134K | 36.3% | 2,387 |
| 2026-10-15 | 32K | 96K | 32.8% | 0 |
| 2026-10-14 | 64K | 267K | 24.1% | 0 |
| 2026-10-13 | 92K | 256K | 35.8% | 11,306 |
| 2026-10-12 | 16K | 55K | 29.5% | 0 |
| 2026-10-09 | 23K | 103K | 22.1% | 67 |
| 2026-10-08 | 50K | 118K | 42.8% | 140 |
| 2026-10-07 | 31K | 83K | 37.8% | 1,000 |
| 2026-10-06 | 66K | 141K | 46.8% | 2 |
| 2026-10-05 | 88K | 200K | 43.8% | 0 |
| 2026-10-02 | 50K | 185K | 27.1% | 4 |
| 2026-10-01 | 50K | 165K | 30.1% | 0 |
| 2026-09-30 | 48K | 128K | 37.1% | 300 |
| 2026-09-29 | 64K | 139K | 45.8% | 3,514 |
| 2026-09-28 | 47K | 155K | 30.5% | 1 |
| 2026-09-25 | 46K | 123K | 37.3% | 500 |
| 2026-09-24 | 49K | 108K | 45.7% | 271 |
| 2026-09-23 | 40K | 151K | 26.1% | 0 |
| 2026-09-22 | 30K | 103K | 29.1% | 10,111 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in FBIO is 985 shares, down 6,044 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (16 September 2026) to 47,185 shares (25 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 985 | $1.95 | $2K |
| 2026-10-13 | 7,029 | $2.11 | $15K |
| 2026-10-05 | 1,062 | $2.03 | $2K |
| 2026-10-02 | 1,106 | $2.07 | $2K |
| 2026-10-01 | 1,229 | $2.14 | $3K |
| 2026-09-30 | 476 | $2.20 | $1K |
| 2026-09-29 | 878 | $2.17 | $2K |
| 2026-09-23 | 37,524 | $2.45 | $92K |
| 2026-09-21 | 1,542 | $2.51 | $4K |
| 2026-09-16 | 6 | $2.49 | $15 |
| 2026-09-15 | 870 | $2.53 | $2K |
| 2026-09-11 | 3,111 | $2.57 | $8K |
| 2026-09-10 | 28,093 | $2.63 | $74K |
| 2026-09-08 | 1,897 | $2.72 | $5K |
| 2026-09-04 | 1,261 | $2.71 | $3K |
| 2026-09-03 | 508 | $2.73 | $1K |
| 2026-09-02 | 1,818 | $2.68 | $5K |
| 2026-09-01 | 2,956 | $2.74 | $8K |
| 2026-08-31 | 13,328 | $2.77 | $37K |
| 2026-08-28 | 16,951 | $2.80 | $47K |
| 2026-08-27 | 29,343 | $2.81 | $82K |
| 2026-08-26 | 20,385 | $2.83 | $58K |
| 2026-08-25 | 47,185 | $2.93 | $138K |
| 2026-08-24 | 296 | $2.87 | $850 |
| 2026-08-21 | 6,522 | $2.77 | $18K |
| 2026-08-20 | 5,368 | $2.85 | $15K |
| 2026-08-19 | 17,772 | $2.91 | $52K |
| 2026-08-18 | 19,478 | $2.82 | $55K |
| 2026-08-17 | 26,213 | $2.93 | $77K |
| 2026-08-14 | 17,820 | $2.98 | $53K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for FBIO in the last 90 days. The most recent filings are listed below. Latest filing: Jin David (Chief Financial Officer) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Jin David | Chief Financial Officer | Grant | 1K | $1.82 | $2K | 1.7M |
| 2026-06-22 | Jin David | Chief Financial Officer | Grant | 400K | $0.00 | $0 | 1.7M |
| 2026-04-01 | Jin David | Chief Financial Officer | Grant | 3K | $2.18 | $6K | 1.3M |
| 2026-03-18 | WEISS MICHAEL S | Executive Vice Chairman | Grant | 475K | $0.00 | $0 | 2.3M |
| 2026-03-18 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Grant | 475K | $0.00 | $0 | 4.6M |
| 2026-01-01 | Lorenz Kevin | Director | Grant | 27K | $0.00 | $0 | 101K |
| 2026-01-01 | Klein Dov | Director | Grant | 27K | $0.00 | $0 | 130K |
| 2026-01-01 | Harvey Jimmie | Director | Grant | 27K | $0.00 | $0 | 147K |
| 2026-01-01 | Hoenlein Malcolm | Director | Grant | 27K | $0.00 | $0 | 116K |
| 2026-01-01 | LOBELL J JAY | Director | Grant | 27K | $0.00 | $0 | 192K |
| 2025-10-01 | Jin David | Chief Financial Officer | Grant | 3K | $1.31 | $4K | 1.2M |
| 2025-04-01 | Jin David | Chief Financial Officer | Grant | 5K | $1.22 | $6K | 1.2M |
| 2025-01-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Grant | 454K | $0.00 | $0 | 4.1M |
| 2025-01-01 | WEISS MICHAEL S | Executive Vice Chairman | Grant | 454K | $0.00 | $0 | 1.8M |
| 2025-01-01 | Hoenlein Malcolm | Director | Grant | 49K | $0.00 | $0 | 88K |
| 2025-01-01 | Lorenz Kevin | Director | Grant | 49K | $0.00 | $0 | 74K |
| 2025-01-01 | Harvey Jimmie | Director | Grant | 49K | $0.00 | $0 | 119K |
| 2025-01-01 | Lu Lucy | Director | Grant | 49K | $0.00 | $0 | 61K |
| 2025-01-01 | Klein Dov | Director | Grant | 49K | $0.00 | $0 | 103K |
| 2025-01-01 | LOBELL J JAY | Director | Grant | 49K | $0.00 | $0 | 165K |
| 2024-12-19 | Jin David | Chief Financial Officer | Grant | 1.0M | $0.00 | $0 | 1.2M |
| 2024-10-01 | Jin David | Chief Financial Officer | Grant | 3K | $1.23 | $3K | 241K |
| 2024-09-23 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Buy | 763K | $1.84 | $1.4M | 3.7M |
| 2024-07-11 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 5K | $7.48 | $37K | 128K |
| 2024-07-10 | Jin David | Chief Financial Officer | Buy | 500 | $7.50 | $4K | 500 |
| 2024-07-09 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 5K | $7.39 | $37K | 123K |
| 2024-07-08 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 5K | $7.35 | $37K | 118K |
| 2024-06-28 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 20K | $1.64 | $33K | 2.9M |
| 2024-05-20 | Klein Dov | Director | Sell | 10K | $1.89 | $19K | 53K |
| 2024-05-16 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 10K | $1.76 | $18K | 2.9M |
| 2024-04-01 | Jin David | Chief Financial Officer | Grant | 2K | $1.70 | $4K | 238K |
| 2024-01-05 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 50K | $2.38 | $119K | 2.9M |
| 2024-01-01 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Grant | 216K | $0.00 | $0 | 2.8M |
| 2024-01-01 | Rowinsky Eric K | Director | Grant | 7K | $0.00 | $0 | 69K |
| 2024-01-01 | WEISS MICHAEL S | See Remarks | Grant | 216K | $0.00 | $0 | 1.3M |
| 2024-01-01 | Harvey Jimmie | Director | Grant | 7K | $0.00 | $0 | 70K |
| 2024-01-01 | Hoenlein Malcolm | Director | Grant | 3K | $0.00 | $0 | 39K |
| 2024-01-01 | Klein Dov | Director | Grant | 7K | $0.00 | $0 | 63K |
| 2024-01-01 | LOBELL J JAY | Director | Grant | 7K | $0.00 | $0 | 116K |
| 2024-01-01 | Lorenz Kevin | Director | Grant | 3K | $0.00 | $0 | 24K |
| 2024-01-01 | Lu Lucy | Director | Grant | 3K | $0.00 | $0 | 12K |
| 2023-12-20 | Jin David | Chief Financial Officer | Grant | 140K | $0.00 | $0 | 236K |
| 2023-11-14 | WEISS MICHAEL S | See Remarks | Buy | 147K | $1.70 | $250K | 1.1M |
| 2023-11-14 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 1.6M | $1.70 | $2.7M | 2.6M |
| 2023-09-26 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 100K | $0.28 | $28K | 15.4M |
| 2023-08-18 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 10K | $9.34 | $93K | 113K |
| 2023-08-17 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 10K | $11.75 | $118K | 103K |
| 2023-02-10 | Jin David | Chief Financial Officer | Buy | 36K | $0.84 | $30K | 1.4M |
| 2023-02-10 | LOBELL J JAY | Director | Buy | 299K | $0.84 | $251K | 1.6M |
| 2023-02-10 | Lu Lucy | Director | Buy | 12K | $0.84 | $10K | 133K |
| 2023-02-10 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Buy | 2.4M | $0.84 | $2.0M | 15.3M |
| 2023-02-10 | Rowinsky Eric K | Director | Buy | 12K | $0.84 | $10K | 932K |
| 2023-02-10 | WEISS MICHAEL S | See Remarks | Buy | 1.2M | $0.84 | $1.0M | 14.8M |
| 2023-01-01 | Harvey Jimmie | Director | Grant | 100K | $0.00 | $0 | 950K |
| 2023-01-01 | Hoenlein Malcolm | Director | Grant | 50K | $0.00 | $0 | 536K |
| 2023-01-01 | Klein Dov | Director | Grant | 100K | $0.00 | $0 | 851K |
| 2023-01-01 | LOBELL J JAY | Director | Grant | 100K | $0.00 | $0 | 1.3M |
| 2023-01-01 | Lorenz Kevin | Director | Grant | 50K | $0.00 | $0 | 315K |
| 2023-01-01 | Rowinsky Eric K | Director | Grant | 100K | $0.00 | $0 | 920K |
| 2023-01-01 | WEISS MICHAEL S | See Remarks | Grant | 1.2M | $0.00 | $0 | 13.6M |
| 2023-01-01 | Lu Lucy | Director | Grant | 50K | $0.00 | $0 | 121K |
| 2023-01-01 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Grant | 1.2M | $0.00 | $0 | 13.0M |
| 2022-12-16 | Lu Lucy | Director | Grant | 30K | $0.00 | $0 | 71K |
| 2022-12-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Buy | 100K | $0.68 | $68K | 11.7M |
| 2022-11-30 | Jin David | Chief Financial Officer | Buy | 5K | $0.56 | $3K | 1.4M |
| 2022-11-30 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Buy | 5K | $0.56 | $3K | 11.6M |
| 2022-10-26 | Jin David | Chief Financial Officer | Grant | 1.4M | $0.00 | $0 | 1.4M |
| 2022-10-21 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Buy | 100K | $0.70 | $70K | 11.6M |
| 2022-06-01 | ROSENWALD LINDSAY A MD | President, CEO & Chairman | Grant | 4K | $0.73 | $3K | 11.7M |
| 2022-01-01 | Rowinsky Eric K | Director | Grant | 100K | $0.00 | $0 | 820K |
| 2022-01-01 | LOBELL J JAY | Director | Grant | 100K | $0.00 | $0 | 1.2M |
| 2022-01-01 | Harvey Jimmie | Director | Grant | 100K | $0.00 | $0 | 850K |
| 2022-01-01 | Lorenz Kevin | Director | Grant | 50K | $0.00 | $0 | 265K |
| 2022-01-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Grant | 1.1M | $0.00 | $0 | 11.5M |
| 2022-01-01 | Hoenlein Malcolm | Director | Grant | 50K | $0.00 | $0 | 486K |
| 2022-01-01 | WEISS MICHAEL S | See Remarks | Grant | 1.1M | $0.00 | $0 | 12.3M |
| 2022-01-01 | Klein Dov | Director | Grant | 100K | $0.00 | $0 | 751K |
| 2021-12-28 | Klein Dov | Director | Sell | 5K | $2.45 | $12K | 651K |
| 2021-12-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Grant | 1K | $2.42 | $3K | 10.4M |
| 2021-11-16 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Other transaction | 5K | $0.00 | $0 | 10.4M |
| 2021-11-16 | Hoenlein Malcolm | Director | Other transaction | 230 | $0.00 | $0 | 436K |
| 2021-11-16 | Klein Dov | Director | Other transaction | 230 | $0.00 | $0 | 656K |
| 2021-09-30 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Other transaction | 8K | $0.00 | $0 | 10.4M |
| 2021-09-30 | Hoenlein Malcolm | Director | Other transaction | 406 | $0.00 | $0 | 435K |
| 2021-09-30 | Klein Dov | Director | Other transaction | 480 | $0.00 | $0 | 656K |
| 2021-09-21 | Hunter Robyn | Chief Financial Officer | Sell | 28K | $3.13 | $89K | 164K |
| 2021-08-05 | Klein Dov | Director | Other transaction | 305 | $0.00 | $0 | 655K |
| 2021-06-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Grant | 1K | $2.31 | $3K | 10.4M |
| 2021-03-02 | Rowinsky Eric K | Director | Sell | 10K | $4.45 | $45K | 720K |
| 2021-02-19 | Rowinsky Eric K | Director | Sell | 8K | $4.31 | $34K | 730K |
| 2021-02-18 | Rowinsky Eric K | Director | Sell | 6K | $4.20 | $25K | 738K |
| 2021-02-16 | Rowinsky Eric K | Director | Sell | 2K | $3.86 | $8K | 744K |
| 2021-02-05 | Rowinsky Eric K | Director | Sell | 4K | $3.80 | $15K | 746K |
| 2021-01-01 | Harvey Jimmie | Director | Grant | 100K | $0.00 | $0 | 750K |
| 2021-01-01 | Hoenlein Malcolm | Director | Grant | 50K | $0.00 | $0 | 435K |
| 2021-01-01 | Klein Dov | Director | Grant | 100K | $0.00 | $0 | 655K |
| 2021-01-01 | LOBELL J JAY | Director | Grant | 100K | $0.00 | $0 | 1.1M |
| 2021-01-01 | Lorenz Kevin | Director | Buy | 50K | $0.00 | $0 | 215K |
| 2021-01-01 | ROSENWALD LINDSAY A MD | PRESIDENT, CEO & CHAIRMAN | Grant | 1.0M | $0.00 | $0 | 10.4M |
| 2021-01-01 | Rowinsky Eric K | Director | Grant | 100K | $0.00 | $0 | 750K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of FBIO in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Lindsay A. Rosenwald, M.D. at 20.7% of the class (6,917,715 shares), filed 2026-03-20 for an event on 2026-03-18.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-29 | 13G/Ano. 1 | Israel A. Englanderindividual | 2.2M | 6.5% | 2026-09-30 |
| 2026-10-29 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 2.2M | 6.5% | 2026-09-30 |
| 2026-10-29 | 13G/Ano. 1 | Millennium Management LLCother entity | 2.2M | 6.5% | 2026-09-30 |
| 2026-10-29 | 13G/Ano. 1 | Integrated Core Strategies (US) LLCother entity | 2.2M | 6.5% | 2026-09-30 |
| 2026-05-15 | 13G/Ano. 1 | Highbridge Capital Management, LLCinvestment adviser, other entity | 2.7M | 7.8% | 2026-03-31 |
| 2026-03-20 | 13D/Ano. 5 | Lindsay A. Rosenwald, M.D.individual | 6.9M | 20.7% | 2026-03-18 |
13F holders
Tracked managers holding FBIO at their latest 13F. JSON3 of the 30 tracked managers held FBIO at their latest 13F, $1.2M in total at quarter-end prices. Two Sigma Investments is the largest at $654K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 214K | $654K | 0.00% | +17K |
| Renaissance Technologies | 2026-06-30 | 86K | $264K | 0.00% | -13K |
| Citadel Advisors | 2026-06-30 | 77K | $236K | 0.00% | -103K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Fortress Biotech in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Fortress Biotech (FBIO), SEC CIK 1429260, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1429260Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of FBIO is sold short?
4,522,696 shares were held short at the 2026-10-15 settlement, 16.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is FBIO's daily short volume?
On 2026-11-02, 48,939 of the 91,393 FBIO shares reported to FINRA were sold short, 53.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does FBIO have fails to deliver?
The SEC's latest file shows 985 FBIO shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are FBIO insiders buying or selling?
No open-market insider trades were reported for FBIO in the last 90 days. The most recent filings are listed below. Latest filing: Jin David (Chief Financial Officer) on 2026-10-01.
Who owns 5% or more of FBIO?
6 holders report 5% or more of FBIO in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Lindsay A. Rosenwald, M.D. at 20.7% of the class (6,917,715 shares), filed 2026-03-20 for an event on 2026-03-18.
Which tracked 13F managers own FBIO?
3 of the 30 tracked 13F managers held FBIO shares at their latest filing, $1.2M in all. The largest: Two Sigma Investments (214K shares, $654K), Renaissance Technologies (86K shares, $264K), Ken Griffin's Citadel Advisors (77K shares, $236K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.